260 related articles for article (PubMed ID: 8649766)
1. Analysis of genomic instability in Li-Fraumeni fibroblasts with germline p53 mutations.
Liu PK; Kraus E; Wu TA; Strong LC; Tainsky MA
Oncogene; 1996 Jun; 12(11):2267-78. PubMed ID: 8649766
[TBL] [Abstract][Full Text] [Related]
2. pZ402, an improved SV40-based shuttle vector containing a T-antigen mutant unable to interact with wild-type p53.
Kraus E; Strong LC; Tainsky MA
Gene; 1998 May; 211(2):229-34. PubMed ID: 9602136
[TBL] [Abstract][Full Text] [Related]
3. Tissue-specific expression of SV40 in tumors associated with the Li-Fraumeni syndrome.
Malkin D; Chilton-MacNeill S; Meister LA; Sexsmith E; Diller L; Garcea RL
Oncogene; 2001 Jul; 20(33):4441-9. PubMed ID: 11494139
[TBL] [Abstract][Full Text] [Related]
4. In vitro transformation of Li-Fraumeni syndrome fibroblasts by SV40 large T antigen mutants.
Maclean K; Rogan EM; Whitaker NJ; Chang AC; Rowe PB; Dalla-Pozza L; Symonds G; Reddel RR
Oncogene; 1994 Mar; 9(3):719-25. PubMed ID: 8108114
[TBL] [Abstract][Full Text] [Related]
5. Detection of both mutant and wild-type p53 protein in normal skin fibroblasts and demonstration of a shared 'second hit' on p53 in diverse tumors from a cancer-prone family with Li-Fraumeni syndrome.
Srivastava S; Tong YA; Devadas K; Zou ZQ; Sykes VW; Chen Y; Blattner WA; Pirollo K; Chang EH
Oncogene; 1992 May; 7(5):987-91. PubMed ID: 1373881
[TBL] [Abstract][Full Text] [Related]
6. Li-Fraumeni syndrome fibroblasts homozygous for p53 mutations are deficient in global DNA repair but exhibit normal transcription-coupled repair and enhanced UV resistance.
Ford JM; Hanawalt PC
Proc Natl Acad Sci U S A; 1995 Sep; 92(19):8876-80. PubMed ID: 7568035
[TBL] [Abstract][Full Text] [Related]
7. UV-induced mutations of supF gene on a shuttle vector plasmid in p53-deficient mouse cells are qualitatively different from those in wild-type cells.
Ishizaki K; Nishizawa K; Mimaki S; Aizawa S
Mutat Res; 1996 Sep; 364(1):43-9. PubMed ID: 8814337
[TBL] [Abstract][Full Text] [Related]
8. Telomerase activity during spontaneous immortalization of Li-Fraumeni syndrome skin fibroblasts.
Gollahon LS; Kraus E; Wu TA; Yim SO; Strong LC; Shay JW; Tainsky MA
Oncogene; 1998 Aug; 17(6):709-17. PubMed ID: 9715272
[TBL] [Abstract][Full Text] [Related]
9. Kinds and spectrum of mutations induced by 1-nitrosopyrene adducts during plasmid replication in human cells.
Yang JL; Maher VM; McCormick JJ
Mol Cell Biol; 1988 Aug; 8(8):3364-72. PubMed ID: 3062380
[TBL] [Abstract][Full Text] [Related]
10. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles.
Yin Y; Tainsky MA; Bischoff FZ; Strong LC; Wahl GM
Cell; 1992 Sep; 70(6):937-48. PubMed ID: 1525830
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of functional inactivation of a Li-Fraumeni syndrome p53 that has a mutation outside of the DNA-binding domain.
Gu J; Kawai H; Wiederschain D; Yuan ZM
Cancer Res; 2001 Feb; 61(4):1741-6. PubMed ID: 11245491
[TBL] [Abstract][Full Text] [Related]
12. A germline 2.35 kb deletion of p53 genomic DNA creating a specific loss of the oligomerization domain inherited in a Li-Fraumeni syndrome family.
Plummer SJ; Santibáñez-Koref M; Kurosaki T; Liao S; Noble B; Fain PR; Anton-Culver H; Casey G
Oncogene; 1994 Nov; 9(11):3273-80. PubMed ID: 7936651
[TBL] [Abstract][Full Text] [Related]
13. Extended lifespan and immortalization of human fibroblasts induced by X-ray irradiation.
Tsutsui T; Tanaka Y; Matsudo Y; Hasegawa K; Fujino T; Kodama S; Barrett JC
Mol Carcinog; 1997 Jan; 18(1):7-18. PubMed ID: 9022808
[TBL] [Abstract][Full Text] [Related]
14. p53 germline mutations in Li-Fraumeni syndrome.
Santibáñez-Koref MF; Birch JM; Hartley AL; Jones PH; Craft AW; Eden T; Crowther D; Kelsey AM; Harris M
Lancet; 1991 Dec; 338(8781):1490-1. PubMed ID: 1683921
[TBL] [Abstract][Full Text] [Related]
15. Allele-specific wild-type TP53 expression in the unaffected carrier parent of children with Li-Fraumeni syndrome.
Buzby JS; Williams SA; Schaffer L; Head SR; Nugent DJ
Cancer Genet; 2017 Feb; 211():9-17. PubMed ID: 28279309
[TBL] [Abstract][Full Text] [Related]
16. Cell cycle arrest defect in Li-Fraumeni Syndrome: a mechanism of cancer predisposition?
Williams KJ; Boyle JM; Birch JM; Norton JD; Scott D
Oncogene; 1997 Jan; 14(3):277-82. PubMed ID: 9018113
[TBL] [Abstract][Full Text] [Related]
17. Functional studies of a novel germline p53 splicing mutation identified in a patient with Li-Fraumeni-like syndrome.
Piao J; Sakurai N; Iwamoto S; Nishioka J; Nakatani K; Komada Y; Mizutani S; Takagi M
Mol Carcinog; 2013 Oct; 52(10):770-6. PubMed ID: 22495821
[TBL] [Abstract][Full Text] [Related]
18. Germ-line exclusion of a single p53 allele by premature termination of translation in a Li-Fraumeni syndrome family.
Stolzenberg MC; Brugières L; Gardes M; Dessarps-Freichey F; Chompret A; Bressac B; Lenoir G; Bonaïti-Pellié C; Lemerle J; Feunteun J
Oncogene; 1994 Oct; 9(10):2799-804. PubMed ID: 8084585
[TBL] [Abstract][Full Text] [Related]
19. The Li-Fraumeni syndrome (LFS): a model for the initiation of p53 signatures in the distal Fallopian tube.
Xian W; Miron A; Roh M; Semmel DR; Yassin Y; Garber J; Oliva E; Goodman A; Mehra K; Berkowitz RS; Crum CP; Quade BJ
J Pathol; 2010 Jan; 220(1):17-23. PubMed ID: 19834951
[TBL] [Abstract][Full Text] [Related]
20. N-methyl-N-nitrosourea-induced mutations in a shuttle plasmid replicated in human cells.
Sikpi MO; Waters LC; Kraemer KH; Preston RJ; Mitra S
Mol Carcinog; 1990; 3(1):30-6. PubMed ID: 2157457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
